PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Pentostatin

Drugs in development · updated 30 October 2026

Pentostatin: clinical trials and development status

Other names and codes: Nipent

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Pentostatin is in 6 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is II.

6Active trials
IIMost advanced phase
13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pentostatin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Sickle-cell diseaseII3NCT02105766
Graft-versus-host diseaseII2NCT02105766
ThalassemiaII2NCT02105766
Autoimmune diseaseII1NCT03663933
Common variable immunodeficiencyII1NCT03663933
Hairy cell leukemiaII1NCT01059786
Immune System DiseasesII1NCT03663933
Lymphoproliferative disordersII1NCT03663933
Opportunistic infectionII1NCT03663933
Residual neoplasmII1NCT01059786
T cell immunodeficiency primaryII1NCT03663933
Aplastic anemiaI1NCT05757310
HemoglobinopathiesI1NCT03249831

Everything on Pentostatin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch